India, Nov. 6 -- This Small-Cap Pharma Stock, engaged in the research, development, manufacturing, and marketing of pharmaceutical APIs, corticosteroids, steroidal hormones, complex injectables, and biotechnology-based products, along with contract development and manufacturing services, hit a 20 percent upper circuit after the company reported strong September quarterly results with a 267.85 percent YoY increase in net profit, along with signing a 10-year take-or-pay manufacturing agreement with a European alternative protein company

With a market capitalization of Rs. 9,688.86 crores, the shares of Symbiotec Pharmalab Limited hit a 20 percent upper circuit of Rs. 1,525 per share on Friday, up from its previous closing price of Rs. 1,2...